Table 3. Summary of effects of various modulators of PFK activity on each human PFK isoform.
| Metabolite | PFK-M | PFK-L | PFK-P | |
|---|---|---|---|---|
| AMP (1200 µM) | kcatATP/K0.5ATP (s−1 µM−1) | −12% | +9% | +220% |
| kcatF6P/K0.5F6P (s−1 µM−1) | −25% | +766% | +162% | |
| ADP (600 µM) | kcatATP/K0.5ATP (s−1 µM−1) | −52% | −47% | +39% |
| kcatF6P/K0.5F6P (s−1 µM−1) | −13% | +157% | +129% | |
| GDP (1100 µM) | kcatATP/K0.5ATP (s−1 µM−1) | +4.3% | −48% | −0.2% |
| kcatF6P/K0.5F6P (s−1 µM−1) | ND | ND | ND | |
| F26BP (10 µM) | kcatATP/K0.5ATP (s−1 µM−1) | −7.4% | +6.5% | +88% |
| kcatF6P/K0.5F6P (s−1 µM−1) | +82% | +148% | +111% | |
| Citrate (600 µM) | kcatATP/K0.5ATP (s−1 µM−1) | +5% | +28% | +136% |
| kcatF6P/K0.5F6P (s−1 µM−1) | −36% | +2% | −78% | |
| PEP (1100 µM) | kcatATP/K0.5ATP (s−1 µM−1) | −11% | +1% | −40% |
| kcatF6P/K0.5F6P (s−1 µM−1) | −7% | +92% | +9% | |
Effect of modulators with respect to ATP and F6P, as measured by percentage changes in specificity constants compared with control PFK without modulator (absolute values in Table 2).